ANTI-INFECTIVE CATHETERS
Anti-infective catheters are provided. Such catheters comprise a composition that comprises a pyrimidine analog, polyurethane, and cellulose or a cellulose-derived polymer, for example, in form of a coating. In addition, anti-infective compositions and methods of making and using anti-infective catheters are provided.
1 . An anti-infective device comprising:
(i) a catheter; and
(ii) a composition on the catheter, the composition comprising:
(a) a polyurethane,
(b) a cellulose or cellulose-derived polymer, and
(c) a pyrimidine analog,
wherein the weight ratio of the polyurethane to the cellulose or cellulose-derived polymer in the composition ranges from 1:10 to 2:1, and the pyrimidine analog is in an amount effective in reducing or inhibiting infection associated with the catheter.
2 . The anti-infective device of claim 1 , wherein the composition is on the catheter in form of a coating.
3 . The anti-infective device of claim 1 , wherein the weight ratio of the polyurethane to the cellulose or cellulose-derived polymer in the composition ranges from 1:2 to 1:4.
4 . (canceled)
5 . The anti-infective device of claim 1 , wherein the pyrimidine analog is released from the composition at an amount effective in reducing or inhibiting infection associated with the catheter for at least 1 week.
6 - 8 . (canceled)
9 . The anti-infective device of claim 1 , wherein the weight ratio of the pyrimidine analog to the sum of the polyurethane and the cellulose or cellulose-derived polymer in the composition ranges from 2% to 40%.
10 - 11 . (canceled)
12 . The anti-infective device of claim 1 , wherein the pyrimidine analog is present at 0.1 μg to 1 mg per cm 2 of the catheter surface area to which the composition is applied or incorporated.
13 . (canceled)
14 . The anti-infective device of claim 1 , wherein the pyrimidine analog is present at 10 μg to 100 μg per cm 2 of the catheter surface area to which the composition is applied or incorporated.
15 . The anti-infective device of claim 1 , wherein the pyrimidine analog is present at 0.1 μg to 2 mg per cm of the catheter length to which the composition is applied or incorporated.
16 . The anti-infective device of claim 1 , wherein the pyrimidine analog is present at 50 μg to 150 mg per cm of the catheter length to which the composition is applied or incorporated.
17 . The anti-infective device of claim 1 , wherein the pyrimidine analog is present at 10 μg to 100 μg per cm of the catheter length to which the composition is applied or incorporated.
18 . (canceled)
19 . The anti-infective device of claim 1 , comprising 1 μg to 250 mg of the pyrimidine analog.
20 - 22 . (canceled)
23 . The anti-infective device of claim 1 , wherein the pyrimidine analog is a fluoropyrimidine.
24 . The anti-infective device of claim 23 , wherein the fluoropyrimidine is selected from the class comprised of 5-fluorouracil and floxuridine.
25 . (canceled)
26 . The anti-infective device of claim 1 , wherein the cellulose-derived polymer is selected from nitrocellulose, cellulose acetate butyrate, and cellulose acetate propionate.
27 . (canceled)
28 . The anti-infective device of claim 1 , wherein the polyurethane is a poly(carbonate urethane), poly(ester urethane), or poly(ether urethane).
29 . (canceled)
30 . The anti-infective device of claim 1 , wherein the composition is only present on the non-luminal surface or a portion thereof.
31 . The anti-infective device of claim 2 , wherein average thickness of the coating ranges from 1 μm to 10 μm.
32 . The anti-infective device of claim 2 , wherein average thickness of the coating ranges from 10 μm to 20 μm.
33 . (canceled)
34 . The anti-infective device of any one of claim 1 , wherein the catheter is a vascular catheter, chronic dwelling gastrointestinal catheter, dialysis catheter, or chronic dwelling genitourinary catheter.
35 - 38 . (canceled)
39 . The anti-infective device of claim 1 , wherein the composition further comprises a second anti-infective agent, an antithrombotic agent, an antiplatelet agent, an anti-inflammatory agent, an immunomodulatory agent, or an anti-fibrotic agent.
40 - 69 . (canceled)
70 . An anti-infective composition comprising at least one polymer and a pyrimidine analog, wherein the pyrimidine analog is selected from the class consisting of 5-fluorouracil and floxuridine.
71 . The anti-infective composition of claim 70 , wherein the pyrimidine analog comprises 2% to 40% by weight of the total composition.
72 . The anti-infective composition of either of claim 70 , wherein the at least one polymer is a cellulose or cellulose-derived polymer.
73 - 75 . (canceled)